Viewing data from:

QUINIDINE SULFATE

ANDA

QUINIDINE SULFATE | A040045 | COSETTE PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Quinidine Sulfate (2023)

Total Spending

$1.7M

Total Claims

2,527

Beneficiaries

676

Avg Cost/Unit

$5.36

Spending Trend

$174K(2019)→$160K(2020)→$137K(2021)→$819K(2022)→$1.7M(2023)

YoY Change:+126.6%

5yr CAGR:+105.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF7 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

BUCHLER GMBHQUINIDINE SULFATE

DMF 36771979

BUCHLER AND COInactiveQUINIDINE SULFATE AND QUINIDINE PRODUCTS

DMF 27591976

PLANTEX LTD CHEMICAL AND PHARMACEUTICAL WORKSInactiveQUINIDINE SULFATE

DMF 28711977

SOCIETE CHIMIQUE POINTET GIRARD SAInactiveQUINIDINE SULFATE

DMF 29021977

DSM MINERA BVInactiveQUINIDINE SULFATE

DMF 33891978

ISLAND CHEMICAL CO INCInactiveQUINIDINE SULFATE USP XX

DMF 37031980

ELAN CORP PLCInactiveQUINIDINE SULFATE SUSTAINED ACTION PELLETS

DMF 61251985

PT SINKONA INDONESIA LESTARIInactiveQUINIDINE SULFATE

DMF 96321992

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 300MG

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Jun 30, 1994

No patent or exclusivity listings for this strength.